author-photo

Alan F. List

University of South Florida

655

Papers

20029

Citations

Citation Trend

Filter By

Papers (472) Sort By

Journal Conference Others

Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)
Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes.

2021 Blood Advances
Show All
- Source
- Cite
- Save
Citations (6)
Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study.

2021 The Lancet Haematology
Show All
- Source
- Cite
- Save
Citations (9)
Dual pyroptotic biomarkers predict erythroid response in lower risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin.

2021 Haematologica
Show All
- Source
- Cite
- Save
Citations (1)
Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes.

2021 Blood Advances
Show All
- Source
- Cite
- Save
Citations (3)
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype.

2020 Blood
Show All
- Source
- Cite
- Save
Citations (25)
Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium.

2020 Cancer Medicine
Show All
- Source
- Cite
- Save
Citations (4)
Luspatercept significantly reduces red blood cell transfusion burden, regardless of gene mutation frequency, spectrum, and prognostic significance, among patients with lower-risk myelodysplastic syndromes enrolled in the MEDALIST trial

2020 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (0)
A sequential two-stage dose escalation study of eltrombopag in patients with myelodysplastic syndrome and thrombocytopenia after hypomethylating agent failure.

2020 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (1)